Hamburg, Germany -7 July 2011: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.
As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against the selected targets. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.
Evotec will receive a fixed research funding fee over the term of collaboration and will be further rewarded on achieving the goals of the research collaboration with early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are extremely pleased that UCB selected Evotec to collaborate on this exciting Drug Discovery Collaboration. This integrated drug discovery deal showcases our CNS disease expertise coupled with our industry leading platform. We look forward to a fruitful collaboration with UCB."
No financial details are disclosed.